Trending...
- Inside the Fight for Affordable Housing: Avery Headley Joins Terran Lamp for a Candid Bronx Leadership Conversation
- UK Financial Ltd Announces A Special Board Meeting Today At 4PM: Orders MCAT Lock on CATEX, Adopts ERC-3643 Standard, & Cancels $0.20 MCOIN for $1
- T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
H.C. Wainwright Initiates Coverage with $34 Price Target, Citing Paradigm Shift in Depression Treatment. NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
MIAMI - eTravelWire -- NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP), a clinical-stage biopharmaceutical company pioneering NMDA-based therapeutics for central nervous system disorders, is emerging as a potential leader in the next generation of depression and suicidality treatments. With its innovative ONE-D (One Day Depression) protocol now launched in Florida and a $40 price target set by H.C. Wainwright, NRXP appears positioned for transformational growth in a rapidly expanding $3.35 billion global market.
A Major Step Forward: ONE-D Depression Treatment Launches in Florida
NRx Pharmaceuticals has initiated the first-in-Florida rollout of the ONE-D (One Day) Depression Treatment, in partnership with Ampa Health. The innovative protocol has shown breakthrough potential in achieving remission from treatment-resistant depression within a single day—an unprecedented leap forward for millions suffering from chronic depression.
Unlike traditional transcranial magnetic stimulation (TMS) therapies requiring up to 90 sessions over three months, the ONE-D approach combines a single-day TMS treatment with physician-prescribed compounds, including D-cycloserine, an active component of NRx's investigational NRX-101, and lisdexamfetamine. Early clinical data show an 87% response rate and 72% remission rate in nonrandomized studies.
The Ampa device is now available across NRXP HOPE Clinics in Sarasota, Naples, and Fort Myers, Florida—with six total locations expected by the end of 2025. This initiative marks one of the first national deployments of the Ampa ONE-D protocol.
More on eTravel Wire
Breakthrough Therapeutic Portfolio: NRX-101 and KETAFREE™
At the center of NRXP's drug pipeline is NRX-101, an FDA-designated Breakthrough Therapy targeting suicidal, treatment-resistant bipolar depression and chronic pain. The drug represents a potentially lifesaving option for the more than 13 million Americans who seriously consider suicide each year, according to the CDC.
NRXP is also advancing KETAFREE™, a preservative-free IV ketamine formulation, through a refiled Abbreviated New Drug Application (ANDA) with the FDA. This comes as the ketamine market—currently valued at $750 million—is projected to reach $3.35 billion globally by 2034.
Importantly, the FDA has granted approval of NRXP's Suitability Petition for its proposed strength of preservative-free ketamine, clearing the path for potential market entry amid ongoing national shortages of sterile ketamine formulations.
Strategic Expansion Through Dura Medical Acquisition
NRXP recently completed its acquisition of Dura Medical, a revenue-generating and EBITDA-positive network of precision psychiatry clinics along Florida's West Coast. The addition of Dura, alongside pending acquisitions such as Neurospa TMS and Cohen & Associates, positions NRXP to deliver an integrated continuum of mental health care spanning TMS, ketamine therapy, and advanced pharmacologic treatments for PTSD, depression, and chronic pain.
Robust Financial and Partnership Outlook
The company's growth strategy is supported by a $7.8 million debt financing deal with Universal Capital, LLC, aimed at expanding NRXP's HOPE Clinic network. In parallel, NRXP has accepted non-binding potential licensing terms for NRX-100, with the agreement representing over $300 million in milestone payments and tiered double-digit royalties—a major value inflection opportunity for investors.
More on eTravel Wire
Moreover, NRXP's partnership with Alvogen Pharmaceuticals supports the ongoing development and commercial readiness of NRX-101, further validating the company's clinical and commercial trajectory.
Analyst Confidence: H.C. Wainwright Issues "Buy" Rating and $40 Price Target
A recent analyst report from H.C. Wainwright & Co. titled "A Paradigm Shift in the Treatment of Depression with Suicidality" initiated coverage on NRx Pharmaceuticals with a Buy rating and a $34 price target. The report underscores NRXP's leadership in transforming how depression and suicidality are treated, leveraging FDA Fast Track and Breakthrough Therapy designations to accelerate commercialization.
"We view NRXP's approach as a paradigm shift in the treatment of depression with suicidality," wrote H.C. Wainwright analysts. "With novel drug candidates, a rapidly expanding clinic network, and strategic licensing opportunities, NRXP is uniquely positioned to capture substantial market share."
About NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing breakthrough therapeutics based on its NMDA receptor modulation platform for the treatment of central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD.
Through its partnerships, innovative clinical pipeline, and integrated treatment model, NRXP is setting new standards in precision psychiatry and interventional mental health care.
For More Information:
Company: NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)
Contact: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Website: www.nrxpharma.com
Phone: (484) 254-6134
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
A Major Step Forward: ONE-D Depression Treatment Launches in Florida
NRx Pharmaceuticals has initiated the first-in-Florida rollout of the ONE-D (One Day) Depression Treatment, in partnership with Ampa Health. The innovative protocol has shown breakthrough potential in achieving remission from treatment-resistant depression within a single day—an unprecedented leap forward for millions suffering from chronic depression.
Unlike traditional transcranial magnetic stimulation (TMS) therapies requiring up to 90 sessions over three months, the ONE-D approach combines a single-day TMS treatment with physician-prescribed compounds, including D-cycloserine, an active component of NRx's investigational NRX-101, and lisdexamfetamine. Early clinical data show an 87% response rate and 72% remission rate in nonrandomized studies.
The Ampa device is now available across NRXP HOPE Clinics in Sarasota, Naples, and Fort Myers, Florida—with six total locations expected by the end of 2025. This initiative marks one of the first national deployments of the Ampa ONE-D protocol.
More on eTravel Wire
- ❄️ Winter Feature: Stay Comfortable at Cold-Weather Events
- Tiger-Rock Martial Arts Appoints Jami Bond as Vice President of Growth
- Super League (N A S D A Q: SLE) Enters Breakout Phase: New Partnerships, Zero Debt & $20 Million Growth Capital Position Company for 2026 Acceleration
- Finland's Gambling Reform Promises "Single-Click" Block for All Licensed Sites
- Private Keys Are a Single Point of Failure: Security Advisor Gideon Cohen Warns MPC Technology Is Now the Only Defense for Institutional Custody
Breakthrough Therapeutic Portfolio: NRX-101 and KETAFREE™
At the center of NRXP's drug pipeline is NRX-101, an FDA-designated Breakthrough Therapy targeting suicidal, treatment-resistant bipolar depression and chronic pain. The drug represents a potentially lifesaving option for the more than 13 million Americans who seriously consider suicide each year, according to the CDC.
NRXP is also advancing KETAFREE™, a preservative-free IV ketamine formulation, through a refiled Abbreviated New Drug Application (ANDA) with the FDA. This comes as the ketamine market—currently valued at $750 million—is projected to reach $3.35 billion globally by 2034.
Importantly, the FDA has granted approval of NRXP's Suitability Petition for its proposed strength of preservative-free ketamine, clearing the path for potential market entry amid ongoing national shortages of sterile ketamine formulations.
Strategic Expansion Through Dura Medical Acquisition
NRXP recently completed its acquisition of Dura Medical, a revenue-generating and EBITDA-positive network of precision psychiatry clinics along Florida's West Coast. The addition of Dura, alongside pending acquisitions such as Neurospa TMS and Cohen & Associates, positions NRXP to deliver an integrated continuum of mental health care spanning TMS, ketamine therapy, and advanced pharmacologic treatments for PTSD, depression, and chronic pain.
Robust Financial and Partnership Outlook
The company's growth strategy is supported by a $7.8 million debt financing deal with Universal Capital, LLC, aimed at expanding NRXP's HOPE Clinic network. In parallel, NRXP has accepted non-binding potential licensing terms for NRX-100, with the agreement representing over $300 million in milestone payments and tiered double-digit royalties—a major value inflection opportunity for investors.
More on eTravel Wire
- Compliance Is the Ticket to Entry: Legal Advisor Gabriela Moraes Analyzes RWA Securitization Paths Under Brazil's New Legislation
- Coalition and CCHR Call on FDA to Review Electroshock Device and Consider a Ban
- Spark Announces 2025 Design Award Winners
- NEW Luxury Single-Family Homes Coming Soon to Manalapan - Pre-Qualify Today for Priority Appointments
- Dominic Pace Returns to the NCIS Franchise With Guest Role on NCIS: Origins
Moreover, NRXP's partnership with Alvogen Pharmaceuticals supports the ongoing development and commercial readiness of NRX-101, further validating the company's clinical and commercial trajectory.
Analyst Confidence: H.C. Wainwright Issues "Buy" Rating and $40 Price Target
A recent analyst report from H.C. Wainwright & Co. titled "A Paradigm Shift in the Treatment of Depression with Suicidality" initiated coverage on NRx Pharmaceuticals with a Buy rating and a $34 price target. The report underscores NRXP's leadership in transforming how depression and suicidality are treated, leveraging FDA Fast Track and Breakthrough Therapy designations to accelerate commercialization.
"We view NRXP's approach as a paradigm shift in the treatment of depression with suicidality," wrote H.C. Wainwright analysts. "With novel drug candidates, a rapidly expanding clinic network, and strategic licensing opportunities, NRXP is uniquely positioned to capture substantial market share."
About NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing breakthrough therapeutics based on its NMDA receptor modulation platform for the treatment of central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD.
Through its partnerships, innovative clinical pipeline, and integrated treatment model, NRXP is setting new standards in precision psychiatry and interventional mental health care.
For More Information:
Company: NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)
Contact: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Website: www.nrxpharma.com
Phone: (484) 254-6134
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
0 Comments
Latest on eTravel Wire
- From Cheer to Courtroom: The Hidden Legal Risks in Your Holiday Eggnog
- Controversial Vegan Turns Rapper Launches First Song, "Psychopathic Tendencies."
- Inside the Fight for Affordable Housing: Avery Headley Joins Terran Lamp for a Candid Bronx Leadership Conversation
- Canterbury Hotel Group Announces the Opening of the TownePlace Suites by Marriott Portland Airport
- Heritage at South Brunswick's Resort-Style Amenities for Any Age and Every Lifestyle
- Georgia's Lanier Islands Resort Pops the Cork on Two Wonderful Ways to Ring in the New Year
- T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
- Record Revenues, Debt-Free Momentum & Shareholder Dividend Ignite Investor Attention Ahead of 2026–2027 Growth Targets: IQSTEL (N A S D A Q: IQST)
- New YouTube Channel Pair Launches to Bring Entertainment Nostalgia Back to Life
- BRAG Hosts Holiday Benefit — Awards 10 Student Scholarships & Honors Timberland with the Corporate Impact Award
- FittingPros Launches Industry's First Data-Driven Golf Club Fitting Directory
- Take Control of Your Color Matching with Boston Industrial Solutions' Newly Expanded Natron® UVPX Series Ink Colors
- "Dr. Vincent Michael Malfitano Expands Monterey–Sicily Cultural Diplomacy With Major International Media Engagement"
- Kaufman Development Breaks Ground on Detroit Micro Data Center, Expanding Its National AI Platform
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
- $80M+ Backlog as Florida Statewide Contract, Federal Wins, and Strategic Alliance Fuel Next Phase of AI-Driven Cybersecurity Growth: Cycurion $CYCU
- High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
- Top10Christmas.co.uk Releases the UK Christmas Toy Trends 2025 Report
- Talagat Business Academy Announces Joint Certificate Program With The University of Chicago Booth School of Business
- LocaXion and Asseco CEIT Announce First-to-Market RTLS-Driven Digital Twin Platform for Healthcare, Manufacturing, and Logistics